TABLE 6.3 (
Continued
)
Substrate
Inhibitor
Inducer
Result
Possible interacting protein
Reference
Cyclosporin A
Erythromycin
Increase in AUC
(2.15-fold), increasein bioavailability (36%!
60%), decrease in total
clearance (
13%)
P-gp, CYP3A4
Gupta et al. (1989)
Cyclosporine
Vitamin E
Increase in AUC
(1.61-fold) andC
max
(1.37-fold),
no change in theratio of AUC ofmetabolites to thatof parent drugs
P-gp
Chang et al. (1996)
Dexamethasone Erythromycin
Increase in AUC
(1.24-fold)
P-gp
Kovarik et al. (1998)
Digoxin
Atorvastatin
Increase in AUC
(1.15-fold) and
C
max
(1.2-fold). No change inrenal clearance
P-gp
Boyd et al. (2000)
Digoxin
Rifampin Decrease in AUC
(
30%, po), decrease
in bioavailability(
30%), Increase in
P-gp expressionlevel in duodenum(3.5-fold), no changein
t1/2
, no change
in renal clearance
P-gp
Greiner et al. (1999b)
160